Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization

被引:43
|
作者
Wang, Kai [1 ]
Chen, Qinhua [2 ]
Liu, Nanxin [1 ]
Zhang, Jie [1 ]
Pan, Xiaoyan [1 ]
机构
[1] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Pharm, Xian 710061, Peoples R China
[2] Shenzhen Baoan Authent TCM Therapy Hosp, Dept Pharm, Shenzhen 518101, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Drug resistance; Tumor angiogenesis; Vascular normalization; Anti-angiogenesis inhibitors; Multiplex inhibitors; CANCER; OXYGENATION; METASTASIS; INHIBITION; VEGFR2; DESIGN; TARGET; PFKFB3;
D O I
10.1016/j.drudis.2021.07.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major problem associated with cancer treatment is resistance-prone chemotherapeutic drugs. An increasing number of studies have documented that the occurrence of resistance tends to be associated with abnormal blood vessels. In 2001, Jain proposed the vascular normalization theory, which was recently applied to the drug-resistant treatment of tumors in the clinic. Through the intervention of angiogenesis inhibitors, remodeling the structure and function of abnormal vessels can maximize the efficacy of chemotherapeutic drugs. In this review, we systematically describe the occurrence and progress of tumor angiogenesis, as well as the pathological characteristics of tumor blood vessels. Moreover, druggable targets for vascular normalization and the development of related inhibitors are also outlined.
引用
收藏
页码:2743 / 2753
页数:11
相关论文
共 50 条
  • [1] Recent advances in angiogenesis, anti-angiogenesis and vascular targeting
    Bikfalvi, A
    Bicknell, R
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (12) : 576 - 582
  • [2] Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
    Fukumura, Dai
    Jain, Rakesh K.
    MICROVASCULAR RESEARCH, 2007, 74 (2-3) : 72 - 84
  • [3] Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy
    Sun, Xiaowen
    Deng, Lei
    Lu, You
    CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (01) : 147 - 156
  • [4] Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy
    Xiaowen Sun
    Lei Deng
    You Lu
    Chinese Journal of Cancer Research, 2018, 30 (01) : 147 - 156
  • [5] Editorial: Anti-angiogenesis agents
    Marcinkiewicz, Cezary
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (21) : 2597 - 2598
  • [6] Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy
    Xiao, Mingshu
    Shi, Yueli
    Jiang, Sujing
    Cao, Mengqing
    Chen, Weiyu
    Xu, Yun
    Xu, Zhiyong
    Wang, Kai
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization
    Shan, Yuanyuan
    Si, Ru
    Wang, Jin
    Zhang, Qingqing
    Li, Jing
    Ma, Yuexiang
    Zhang, Jie
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 205
  • [8] Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent
    Wang, Ju Bo
    Wang, Mao De
    Li, En Xiao
    Dong, Dan Feng
    PEPTIDES, 2012, 38 (02) : 457 - 462
  • [9] Inhibition of anti-angiogenesis cardiovascular events and chemotherapy cardiotoxicity by angioprevention agents
    Albini, A.
    Noonan, D.
    Pfeffer, U.
    Lorusso, G.
    Vannini, N.
    THROMBOSIS RESEARCH, 2007, 120 : S141 - S141
  • [10] Limitations of combination anti-angiogenesis and chemotherapy
    Andy Millar
    Nature Reviews Cancer, 2002, 2 (10) : 804 - 804